Asarfi Hospital Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: May 13, 2025, 8:45 pm

Market Cap	186 Cr.
Current Price	94.5
High / Low	112/52.8
Stock P/E	16.9
Book Value	41.4
Dividend Yield	0.00 %
ROCE	16.2 %
ROE	14.5 %
Face Value	10.0
PEG Ratio	-0.46

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Asarfi Hospital Ltd

Competitors of Asarfi Hospital Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Asarfi Hospital Ltd	186 Cr.	94.5	112/52.8	16.9	41.4	0.00 %	16.2 %	14.5 %	10.0
Industry Average	186.00 Cr	94.50		16.90	41.40	0.00%	16.20%	14.50%	10.00

All Competitor Stocks of Asarfi Hospital Ltd

Quarterly Result

Metric	Dec 2023	Dec 2024
Sales	20.05	32.89
Expenses	16.04	25.90
Operating Profit	4.01	6.99
OPM %	20.00%	21.25%
Other Income	1.20	0.89
Interest	0.60	1.18
Depreciation	3.25	3.04
Profit before tax	1.36	3.66
Tax %	102.94%	25.41%
Net Profit	-0.05	2.72
EPS in Rs	-0.03	1.38

Last Updated: February 28, 2025, 3:25 pm

Below is a detailed analysis of the quarterly data for Asarfi Hospital Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is 32.89 Cr.. The value appears strong and on an upward trend. It has increased from 20.05 Cr. (Dec 2023) to 32.89 Cr., marking an increase of 12.84 Cr..
For Expenses, as of Dec 2024, the value is 25.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.04 Cr. (Dec 2023) to 25.90 Cr., marking an increase of 9.86 Cr..
For Operating Profit, as of Dec 2024, the value is 6.99 Cr.. The value appears strong and on an upward trend. It has increased from 4.01 Cr. (Dec 2023) to 6.99 Cr., marking an increase of 2.98 Cr..
For OPM %, as of Dec 2024, the value is 21.25%. The value appears strong and on an upward trend. It has increased from 20.00% (Dec 2023) to 21.25%, marking an increase of 1.25%.
For Other Income, as of Dec 2024, the value is 0.89 Cr.. The value appears to be declining and may need further review. It has decreased from 1.20 Cr. (Dec 2023) to 0.89 Cr., marking a decrease of 0.31 Cr..
For Interest, as of Dec 2024, the value is 1.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.60 Cr. (Dec 2023) to 1.18 Cr., marking an increase of 0.58 Cr..
For Depreciation, as of Dec 2024, the value is 3.04 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3.25 Cr. (Dec 2023) to 3.04 Cr., marking a decrease of 0.21 Cr..
For Profit before tax, as of Dec 2024, the value is 3.66 Cr.. The value appears strong and on an upward trend. It has increased from 1.36 Cr. (Dec 2023) to 3.66 Cr., marking an increase of 2.30 Cr..
For Tax %, as of Dec 2024, the value is 25.41%. The value appears to be improving (decreasing) as expected. It has decreased from 102.94% (Dec 2023) to 25.41%, marking a decrease of 77.53%.
For Net Profit, as of Dec 2024, the value is 2.72 Cr.. The value appears strong and on an upward trend. It has increased from -0.05 Cr. (Dec 2023) to 2.72 Cr., marking an increase of 2.77 Cr..
For EPS in Rs, as of Dec 2024, the value is 1.38. The value appears strong and on an upward trend. It has increased from -0.03 (Dec 2023) to 1.38, marking an increase of 1.41.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: September 23, 2024, 3:00 pm

Metric	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Sales	42.87	54.12	65.19	68.81	80.93
Expenses	36.63	46.08	54.41	55.04	64.61
Operating Profit	6.24	8.04	10.78	13.77	16.32
OPM %	14.56%	14.86%	16.54%	20.01%	20.17%
Other Income	0.29	0.28	0.98	2.33	1.67
Interest	0.53	0.63	0.70	1.34	2.92
Depreciation	2.42	2.91	3.35	3.87	8.78
Profit before tax	3.58	4.78	7.71	10.89	6.29
Tax %	26.54%	25.94%	25.81%	26.35%	33.07%
Net Profit	2.63	3.53	5.73	8.02	4.21
EPS in Rs	21.48	28.83	46.79	5.53	2.14
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	34.22%	62.32%	39.97%	-47.51%
Change in YoY Net Profit Growth (%)	0.00%	28.10%	-22.36%	-87.47%

Asarfi Hospital Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2020-2021 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	23%
3 Years:	23%
TTM:	49%

Compounded Profit Growth
10 Years:	%
5 Years:	33%
3 Years:	24%
TTM:	161%

Stock Price CAGR
10 Years:	%
5 Years:	%
3 Years:	%
1 Year:	28%

Return on Equity
10 Years:	%
5 Years:	16%
3 Years:	14%
Last Year:	14%

Last Updated: Unknown

Balance Sheet

Last Updated: May 13, 2025, 2:13 pm

Month	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	1	1	1	14	20	20
Reserves	12	16	21	27	51	62
Borrowings	5	7	12	17	32	49
Other Liabilities	9	13	28	34	52	34
Total Liabilities	28	37	63	93	154	164
Fixed Assets	18	22	31	39	94	101
CWIP	0	2	9	18	0	2
Investments	0	0	0	0	0	0
Other Assets	9	13	22	37	60	61
Total Assets	28	37	63	93	154	164

Below is a detailed analysis of the balance sheet data for Asarfi Hospital Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is ₹20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 20.00 Cr..
For Reserves, as of Mar 2025, the value is ₹62.00 Cr.. The value appears strong and on an upward trend. It has increased from 51.00 Cr. (Mar 2024) to ₹62.00 Cr., marking an increase of 11.00 Cr..
For Borrowings, as of Mar 2025, the value is ₹49.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 32.00 Cr. (Mar 2024) to ₹49.00 Cr., marking an increase of 17.00 Cr..
For Other Liabilities, as of Mar 2025, the value is ₹34.00 Cr.. The value appears to be improving (decreasing). It has decreased from 52.00 Cr. (Mar 2024) to ₹34.00 Cr., marking a decrease of 18.00 Cr..
For Total Liabilities, as of Mar 2025, the value is ₹164.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 154.00 Cr. (Mar 2024) to ₹164.00 Cr., marking an increase of 10.00 Cr..
For Fixed Assets, as of Mar 2025, the value is ₹101.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Mar 2024) to ₹101.00 Cr., marking an increase of 7.00 Cr..
For CWIP, as of Mar 2025, the value is ₹2.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to ₹2.00 Cr., marking an increase of 2.00 Cr..
For Investments, as of Mar 2025, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Other Assets, as of Mar 2025, the value is ₹61.00 Cr.. The value appears strong and on an upward trend. It has increased from 60.00 Cr. (Mar 2024) to ₹61.00 Cr., marking an increase of 1.00 Cr..
For Total Assets, as of Mar 2025, the value is ₹164.00 Cr.. The value appears strong and on an upward trend. It has increased from 154.00 Cr. (Mar 2024) to ₹164.00 Cr., marking an increase of 10.00 Cr..

Notably, the Reserves (62.00 Cr.) exceed the Borrowings (49.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	2	10	9	7	26	-4
Cash from Investing Activity +	-5	-16	-23	-21	-63	-8
Cash from Financing Activity +	2	6	14	15	36	13
Net Cash Flow	0	0	-0	1	-1	1

Free Cash Flow

Month	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	1.24	1.04	-1.22	-3.23	-15.68

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	20.01	14.16	29.84	89.80	109.41
Inventory Days	23.12	13.20	15.50	25.89	32.33
Days Payable	155.80	22.69	34.13	90.98	445.29
Cash Conversion Cycle	-112.67	4.67	11.22	24.72	-303.55
Working Capital Days	18.05	-7.15	-4.20	51.56	-3.02
ROCE %		25.26%	28.86%	26.19%	11.41%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2023	Mar 2024	Sep 2024
Promoters	61.17%	61.17%	61.17%
DIIs	3.26%	2.33%	1.95%
Public	35.58%	36.50%	36.89%
No. of Shareholders	706	1,261	1,284

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24
FaceValue	10.00
Basic EPS (Rs.)	2.31
Diluted EPS (Rs.)	2.31
Cash EPS (Rs.)	6.58
Book Value[Excl.RevalReserv]/Share (Rs.)	35.78
Book Value[Incl.RevalReserv]/Share (Rs.)	35.78
Revenue From Operations / Share (Rs.)	42.89
PBDIT / Share (Rs.)	9.01
PBIT / Share (Rs.)	4.54
PBT / Share (Rs.)	3.17
Net Profit / Share (Rs.)	2.11
NP After MI And SOA / Share (Rs.)	2.11
PBDIT Margin (%)	20.99
PBIT Margin (%)	10.58
PBT Margin (%)	7.39
Net Profit Margin (%)	4.93
NP After MI And SOA Margin (%)	4.93
Return on Networth / Equity (%)	5.91
Return on Capital Employeed (%)	7.93
Return On Assets (%)	2.70
Long Term Debt / Equity (X)	0.28
Total Debt / Equity (X)	0.45
Current Ratio (X)	1.13
Quick Ratio (X)	1.08
Interest Coverage Ratio (X)	6.58
Interest Coverage Ratio (Post Tax) (X)	2.55
Enterprise Value (Cr.)	142.87
EV / Net Operating Revenue (X)	1.69
EV / EBITDA (X)	8.06
MarketCap / Net Operating Revenue (X)	1.52
Price / BV (X)	1.83
Price / Net Operating Revenue (X)	1.52
EarningsYield	0.03

After reviewing the key financial ratios for Asarfi Hospital Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
For Basic EPS (Rs.), as of Mar 24, the value is 2.31. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Diluted EPS (Rs.), as of Mar 24, the value is 2.31. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Cash EPS (Rs.), as of Mar 24, the value is 6.58. This value is within the healthy range. No previous period data is available for comparison.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 35.78. No previous period data is available for comparison.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 35.78. No previous period data is available for comparison.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 42.89. No previous period data is available for comparison.
For PBDIT / Share (Rs.), as of Mar 24, the value is 9.01. This value is within the healthy range. No previous period data is available for comparison.
For PBIT / Share (Rs.), as of Mar 24, the value is 4.54. This value is within the healthy range. No previous period data is available for comparison.
For PBT / Share (Rs.), as of Mar 24, the value is 3.17. This value is within the healthy range. No previous period data is available for comparison.
For Net Profit / Share (Rs.), as of Mar 24, the value is 2.11. This value is within the healthy range. No previous period data is available for comparison.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 2.11. This value is within the healthy range. No previous period data is available for comparison.
For PBDIT Margin (%), as of Mar 24, the value is 20.99. This value is within the healthy range. No previous period data is available for comparison.
For PBIT Margin (%), as of Mar 24, the value is 10.58. This value is within the healthy range. No previous period data is available for comparison.
For PBT Margin (%), as of Mar 24, the value is 7.39. This value is below the healthy minimum of 10. No previous period data is available for comparison.
For Net Profit Margin (%), as of Mar 24, the value is 4.93. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 4.93. This value is below the healthy minimum of 8. No previous period data is available for comparison.
For Return on Networth / Equity (%), as of Mar 24, the value is 5.91. This value is below the healthy minimum of 15. No previous period data is available for comparison.
For Return on Capital Employeed (%), as of Mar 24, the value is 7.93. This value is below the healthy minimum of 10. No previous period data is available for comparison.
For Return On Assets (%), as of Mar 24, the value is 2.70. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.28. This value is within the healthy range. No previous period data is available for comparison.
For Total Debt / Equity (X), as of Mar 24, the value is 0.45. This value is within the healthy range. No previous period data is available for comparison.
For Current Ratio (X), as of Mar 24, the value is 1.13. This value is below the healthy minimum of 1.5. No previous period data is available for comparison.
For Quick Ratio (X), as of Mar 24, the value is 1.08. This value is within the healthy range. No previous period data is available for comparison.
For Interest Coverage Ratio (X), as of Mar 24, the value is 6.58. This value is within the healthy range. No previous period data is available for comparison.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.55. This value is below the healthy minimum of 3. No previous period data is available for comparison.
For Enterprise Value (Cr.), as of Mar 24, the value is 142.87. No previous period data is available for comparison.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.69. This value is within the healthy range. No previous period data is available for comparison.
For EV / EBITDA (X), as of Mar 24, the value is 8.06. This value is within the healthy range. No previous period data is available for comparison.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.52. This value is within the healthy range. No previous period data is available for comparison.
For Price / BV (X), as of Mar 24, the value is 1.83. This value is within the healthy range. No previous period data is available for comparison.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.52. This value is within the healthy range. No previous period data is available for comparison.
For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. No previous period data is available for comparison.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Asarfi Hospital Ltd as of May 14, 2025 is: 82.78

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of May 14, 2025, Asarfi Hospital Ltd is Overvalued by 12.40% compared to the current share price 94.50

Intrinsic Value of Asarfi Hospital Ltd as of May 14, 2025 is: 52.19

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of May 14, 2025, Asarfi Hospital Ltd is Overvalued by 44.77% compared to the current share price 94.50

Last 5 Year EPS CAGR: -36.95%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 18.34%, which is a positive sign. The stock has a low average Working Capital Days of 11.05, which is a positive sign. The stock has a low average Cash Conversion Cycle of -75.12, which is a positive sign. The company has higher reserves (31.50 cr) compared to borrowings (20.33 cr), indicating strong financial stability. The company has shown consistent growth in sales (62.38 cr) and profit (6.65 cr) over the years.

Strength

Weakness

The stock has a high average ROCE of 18.34%, which is a positive sign.
The stock has a low average Working Capital Days of 11.05, which is a positive sign.
The stock has a low average Cash Conversion Cycle of -75.12, which is a positive sign.
The company has higher reserves (31.50 cr) compared to borrowings (20.33 cr), indicating strong financial stability.
The company has shown consistent growth in sales (62.38 cr) and profit (6.65 cr) over the years.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Asarfi Hospital Ltd:
1. Net Profit Margin: 4.93%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 7.93% (Industry Average ROCE: 16.2%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 5.91% (Industry Average ROE: 14.5%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 2.55
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.08
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 16.9 (Industry average Stock P/E: 16.9)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.45
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Asarfi Hospital Ltd. is a Public Limited Listed company incorporated on 04/10/2005 and has its registered office in the State of Jharkand, India. Company's Corporate Identification Number(CIN) is L85110JH2005PLC011673 and registration number is 011673. Currently Company is involved in the business activities of Hospital activities. Company's Total Operating Revenue is Rs. 120.57 Cr. and Equity Capital is Rs. 19.68 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Hospitals & Medical Services	4th Floor, Asarfi Hospital, Baramuri, B Polytechnic, Dhanbad Jharkand 828130	cs@asarfihospital.com http://www.asarfi.in

Management
Name	Position Held
Mr. Udai Pratap Singh	Managing Director
Mrs. Madhuri Singh	Executive Director
Mr. Gopal Singh	Executive Director
Dr. Sukanti Kumar Das	Non Executive Director
Mrs. Rajkumari Sharma	Independent Director
Mr. Amit Kumar Barnwal	Independent Director

FAQ

What is the intrinsic value of Asarfi Hospital Ltd?

Asarfi Hospital Ltd's intrinsic value (as of 13 May 2025) is ₹82.78 — 12.40% lower the current market price of 94.50, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 186 Cr. market cap, FY2025-2026 high/low of ₹112/52.8, reserves of 62 Cr, and liabilities of 164 Cr.

What is the Market Cap of Asarfi Hospital Ltd?

The Market Cap of Asarfi Hospital Ltd is 186 Cr..

What is the current Stock Price of Asarfi Hospital Ltd as on 13 May 2025?

The current stock price of Asarfi Hospital Ltd as on 13 May 2025 is 94.5.

What is the High / Low of Asarfi Hospital Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Asarfi Hospital Ltd stocks is ₹112/52.8.

What is the Stock P/E of Asarfi Hospital Ltd?

The Stock P/E of Asarfi Hospital Ltd is 16.9.

What is the Book Value of Asarfi Hospital Ltd?

The Book Value of Asarfi Hospital Ltd is 41.4.

What is the Dividend Yield of Asarfi Hospital Ltd?

The Dividend Yield of Asarfi Hospital Ltd is 0.00 %.

What is the ROCE of Asarfi Hospital Ltd?

The ROCE of Asarfi Hospital Ltd is 16.2 %.

What is the ROE of Asarfi Hospital Ltd?

The ROE of Asarfi Hospital Ltd is 14.5 %.

What is the Face Value of Asarfi Hospital Ltd?

The Face Value of Asarfi Hospital Ltd is 10.0.